GlycoFi Inc.

It Is A Risk Thing In times I’ve termed wilderness periods – the stagnant years for biotech stocks after a bubble bursts – investors shy away from exposure to the binary risk and funding requirements

Public Biotech Stocks Bounce Forward And Back Again In the year to date the NASDAQ Biotech Index (NBI) has fallen by nearly 14% compared to the less risky NYSE Arca Pharmaceutical Index’s (DRG’s) fall

As companies with proficiencies in large-molecule R&D survey the landscape for opportunities, they see increasingly competitive specialist disease markets, or still foggy regulatory pathways for biosi

FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitabl